TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03782740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Description: Melatonin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill manufactured to mimic Melatonin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill manufactured to mimic Melatonin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg
Description: Melatonin capsule
Study: NCT03899194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil capsules
Description: fish oil capsules(1000mg，EPA 180mg；DHA 120mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram 10-20 mg/d
Study: NCT00771407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice Reconstructive Matrix
Description: Strattice will be placed as a fascial inlay to support stoma sites

Intervention type: OTHER
Group type: OTHER
Intervention: Standard ostomy creation
Description: Ostomy will be created as routinely performed
Study: NCT02745223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PresbiDrops (CSF-1)
Description: PresbiDrops (CSF-1) is a topical ophthalmic drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
Study: NCT02874690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: single dose methylphenidate; 0.3mg/kg, up to 20mg, rounded to the nearest 2.5mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill identical in appearance to methylphenidate
Study: NCT04109625

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Demonstrator MAGIA
Description: test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Demonstrator MAGIA
Description: test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Demonstrator MAGIA
Description: test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
Study: NCT01443689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Participants will be given conventional therapy only.
Study: NCT01829815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Make the Difference
Description: The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parents Make the Difference
Description: The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children.
Study: NCT03754504

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry powder
Description: 3 capsules /day of whole cranberry powder (500mg/each)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules/day of a placebo comparator
Study: NCT03070015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrisystem
Description: The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI \> 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables \& no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch \& 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (\~50% kcal from carbohydrate,\~25% from protein,\~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed DASH
Description: The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts \& sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day \& men ate 1500 kcal/day. Subjects with BMI \>40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
Study: NCT01731886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous peripheral blood stem cell transplant
Description: Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell collection
Description: Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is \>2500 x 109 cells/liter; platelet count is \>20 x 103/mm3.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell collection
Description: Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is \>2500 x 109 cells/liter; platelet count is \>20 x 103/mm3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
Study: NCT02919618

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy (SBRT)
Description: (Cardiac ablative radiotherapy)
Study: NCT03002207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge
Description: Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
Study: NCT01136148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A medical and mental health unit
Description: A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A medical and mental health unit
Description: A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
Study: NCT00573183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAGE-12
Description: The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT01313858

Intervention type: DRUG
Intervention: Simponi®

Intervention type: DRUG
Intervention: Simponi®

Intervention type: DRUG
Intervention: Simponi®

Intervention type: DRUG
Intervention: Methotrexate
Description: Given concomitantly with Simponi®
Study: NCT01337700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
Study: NCT02899299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study: NCT03002207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge
Description: Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The defect is sutured
Description: Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The defect is sutured
Description: Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
Study: NCT02836249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF 25 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: TDF 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: TAF placebo tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF Placebo
Description: TDF placebo tablet administered orally once daily
Study: NCT02003313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group T
Description: 0.5ml, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Group C
Description: 0.5ml, Intramuscular
Study: NCT05414045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous testicular tissue transplantation of prepubertal frozen testicular tissue
Description: Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells (SSCs).~If patient has a childwish on adult age and in case no spermatozoa are found in the ejaculate or after performing a testicular biopsy (TESE), we will perform autologous testicular tissue transplantation with the primary objective being to restore spermatogenesis and fertility.
Study: NCT03559530

Intervention type: DRUG
Intervention: Antimicrobial
Description: Antimicrobial therapy according to A. baumannii susceptibility profile
Study: NCT04331275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs)
Description: VSTs will be infused into solid organ transplant recipients who have evidence of viral infection.
Study: NCT00508456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temodar (Temozolomide)
Description: 150 mg/m\^2 orally once a day for 7 consecutive days (days 8 through 15).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hominex-2
Description: Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®.
Study: NCT04436835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Undergo ART

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02306252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational and Physical Therapy
Description: OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
Study: NCT03549325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria lactamica
Description: Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neisseria lactamica
Description: Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
Study: NCT00823797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01731886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Mesna will be provided with the cyclophosphamide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: Mesna will be provided with the cyclophosphamide.
Study: NCT03426072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified IHI breakthrough series
Description: There are five main elements to the intervention:~1. Establishment of the team and set up~2. Establishing baseline performance and knowledge~3. Ongoing developmental support~4. Learning sessions (3)~5. Action periods (3)~6. The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support
Study: NCT01805349

Intervention type: RADIATION
Group type: OTHER
Intervention: Hand X-rays
Description: Hand X-rays to assess the digital arthrosis
Study: NCT03265717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INVAC-1
Description: Patients are treated by INVAC-1 for 6 cycles at 4-week intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INVAC-1
Description: Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
Study: NCT01227707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5 mg/kg intravenously every 2 weeks, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 825 mg/m2 twice daily orally, 38 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Total dose of 45 Gy over 38 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesorectal excision
Description: 6-8 weeks after completion of neoadjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
Study: NCT00816829

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fenofibrate-matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 145 mg NanoCrystal tablet
Study: NCT03232268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-mismatched microtransplantation
Description: 3 administrations of hematopoietic stem cells without immunosupression
Study: NCT00748774

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Two questionnaires taking about 10 minutes to complete.
Study: NCT00476645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
Study: NCT00553059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 10 mg IV 30 minutes prior to administration of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 10 mg IV 30 minutes prior to administration of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dronabinol
Description: 5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: 0.25 mg IV 30 minutes prior to administration of chemotherapy
Study: NCT04581395

Intervention type: OTHER
Group type: OTHER
Intervention: non-pretreated Succinylcholine
Description: no pretreatment
Study: NCT04296201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMA treatment
Description: Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMA treatment
Description: Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMA treatment
Description: Each arm will receive the DMA treatment in a specific area on the body to observe immediate effect.
Study: NCT01944384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldactone
Description: aldactone 25 mg for 6 months
Study: NCT04443153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Feedback
Description: Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Feedback
Description: Provides tailored information to the user about what glycemic risk they may be facing as well as how glycemic control and system use looked in the past week. Treatment decision and therapy changes are entirely left to the decision of the user.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decision Support System
Description: CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decision Support System
Description: CGM-based system that includes Personalized Feedback (PF) and further assists with treatment recommendations for common metabolic challenges

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Augmented Mode
Description: A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Augmented Mode
Description: A mode in Diabetes Assistant (DiAs) that combines Diabetes Assistant, Insulin pump or Multiple Daily Injections, CGM, ketone meters, and glycemic treatment guidelines together to manage diabetes.